

Edward M Schaeffer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9605420/publications.pdf>

Version: 2024-02-01

191
papers

8,326
citations

53660

45
h-index

53109

85
g-index

193
all docs

193
docs citations

193
times ranked

10271
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-world use of MRI for risk stratification prior to prostate biopsy. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 353-359.	2.0	8
2	High intratumoral plasma cells content in primary prostate cancer defines a subset of tumors with potential susceptibility to immune-based treatments. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 105-112.	2.0	2
3	Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer. <i>European Urology</i> , 2022, 81, 325-330.	0.9	7
4	A transcriptomic model for homologous recombination deficiency in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 659-665.	2.0	9
5	Reporting of Racial Health Disparities Research: Are We Making Progress?. <i>Journal of Clinical Oncology</i> , 2022, 40, 8-11.	0.8	11
6	Role of Prophylactic Antibiotics in Transperineal Prostate Biopsy: A Systematic Review and Meta-analysis. <i>European Urology Open Science</i> , 2022, 37, 53-63.	0.2	26
7	Association of B7 α expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer. <i>Cancer</i> , 2022, 128, 2269-2280.	2.0	16
8	Grade Migration of Prostate Cancer in the United States During the Last Decade. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1012-1019.	3.0	13
9	Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. <i>European Urology</i> , 2022, 82, 341-351.	0.9	32
10	MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets. <i>Nature Communications</i> , 2022, 13, 2559.	5.8	56
11	Abstract 462: Using attention-based deep multiple instance learning to identify key genetic alterations in prostate cancer from whole slide images. <i>Cancer Research</i> , 2022, 82, 462-462.	0.4	0
12	Somatic HOXB13 Expression Correlates with Metastatic Progression in Men with Localized Prostate Cancer Following Radical Prostatectomy. <i>European Urology Oncology</i> , 2021, 4, 955-962.	2.6	14
13	A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. <i>European Urology</i> , 2021, 79, 374-383.	0.9	93
14	Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer. <i>Modern Pathology</i> , 2021, 34, 1185-1193.	2.9	61
15	Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes. <i>Nature Communications</i> , 2021, 12, 935.	5.8	56
16	NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 134-143.	2.3	299
17	Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. <i>Lancet Oncology</i> , The, 2021, 22, 402-410.	5.1	79
18	Local anaesthetic techniques for performing transperineal prostate biopsy. <i>Nature Reviews Urology</i> , 2021, 18, 315-317.	1.9	5

#	ARTICLE	IF	CITATIONS
19	Cause of death during prostate cancer survivorship: A contemporary, US population-based analysis. <i>Cancer</i> , 2021, 127, 2895-2904.	2.0	24
20	A PRC2-independent function for EZH2 in regulating rRNA 2â€²-O methylation and IRES-dependent translation. <i>Nature Cell Biology</i> , 2021, 23, 341-354.	4.6	54
21	TNF-alpha immunosuppressive use and future malignancy risk.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10558-10558.	0.8	1
22	Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences. <i>Communications Biology</i> , 2021, 4, 670.	2.0	50
23	Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. <i>European Urology</i> , 2021, 79, 717-721.	0.9	13
24	Performance of prostate health index and PSA density in a diverse biopsy-confirmed cohort with mpMRI for detecting significant prostate cancer. <i>BJUI Compass</i> , 2021, 2, 370-376.	0.7	6
25	It's all in the name: Does nomenclature for indolent prostate cancer impact management and anxiety?. <i>Cancer</i> , 2021, 127, 3354-3360.	2.0	5
26	Abstract 2546: Predictive value of prostate health index (PHI) in multi-parametric MRI in an ethnically diverse cohort. , 2021, , .		0
27	Influence of Department Leadership on Scholarly Productivity and Research Funding in Academic Urology. <i>Urology</i> , 2021, 154, 136-140.	0.5	0
28	Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). <i>Cancer Genetics</i> , 2021, 258-259, 61-68.	0.2	2
29	Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men. <i>JAMA Network Open</i> , 2021, 4, e2139769.	2.8	16
30	United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 179-183.	2.0	12
31	Educational Material on Prostate Cancer Screening is Overly Complex and Fails to Meet Recommended Layperson Readability Guidelines. <i>Urology</i> , 2020, 135, 1-3.	0.5	5
32	The Cost of Prostate Biopsies and their Complications: A Summary of Data on All Medicare Fee-for-Service Patients over 2 Years. <i>Urology Practice</i> , 2020, 7, 145-151.	0.2	11
33	Risk Factors for Infection after Prostate Biopsy in the United States. <i>Urology</i> , 2020, 138, 113-118.	0.5	11
34	Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. <i>JCO Precision Oncology</i> , 2020, 4, 1228-1238.	1.5	2
35	Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance. <i>Prostate</i> , 2020, 80, 1012-1023.	1.2	22
36	Assessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in Patients With Prostate Cancer. <i>JAMA Oncology</i> , 2020, 6, 1793.	3.4	10

#	ARTICLE	IF	CITATIONS
37	Racial Differences in Genomic Profiling of Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 1083-1085.	13.9	87
38	Changes in prostate-specific antigen at the time of prostate cancer diagnosis after Medicaid expansion in young men. <i>Cancer</i> , 2020, 126, 3229-3236.	2.0	9
39	Association between inflammatory bowel disease and prostate cancer: A large-scale, population-based study. <i>International Journal of Cancer</i> , 2020, 147, 2735-2742.	2.3	28
40	A novel immunocompetent model of metastatic prostate cancer-induced bone pain. <i>Prostate</i> , 2020, 80, 782-794.	1.2	6
41	Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. <i>European Urology</i> , 2020, 78, 327-332.	0.9	18
42	Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. <i>JAMA Oncology</i> , 2020, 6, 735.	3.4	58
43	Tumor Immune Microenvironment Clusters in Localized Prostate Adenocarcinoma: Prognostic Impact of Macrophage Enriched/Plasma Cell Non-Enriched Subtypes. <i>Journal of Clinical Medicine</i> , 2020, 9, 1973.	1.0	10
44	<i>CDKN1B</i> Deletions are Associated with Metastasis in African American Men with Clinically Localized, Surgically Treated Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2595-2602.	3.2	16
45	Association between surgical approach and survival following resection of abdominopelvic malignancies. <i>Journal of Surgical Oncology</i> , 2020, 121, 620-629.	0.8	2
46	Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 646-653.	2.0	17
47	T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3182-3192.	3.2	64
48	Surgical versus Medical Castration for Metastatic Prostate Cancer: Use and Overall Survival in a National Cohort. <i>Journal of Urology</i> , 2020, 203, 933-939.	0.2	19
49	Differential expression of PSMA and 18F-fluciclovine transporter genes in metastatic castrate-resistant and treatment-emergent small cell/neuroendocrine prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 24-24.	0.8	5
50	Head-to-head comparison between decipher and prolaris tests: Two commercially available post-prostatectomy genomic tests.. <i>Journal of Clinical Oncology</i> , 2020, 38, 348-348.	0.8	1
51	Clinical-genomic sub-classification of high-risk prostate cancer: Implications for tailoring therapy and clinical trial design.. <i>Journal of Clinical Oncology</i> , 2020, 38, 337-337.	0.8	0
52	Characterization of PSMA and 18F-fluciclovine transporter gene expression in localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 295-295.	0.8	0
53	Evaluating the clinical, environmental, genetic, and genomic profile of men with early-onset aggressive prostate cancer (PCa).. <i>Journal of Clinical Oncology</i> , 2020, 38, e17517-e17517.	0.8	0
54	DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway. <i>Clinical Cancer Research</i> , 2019, 25, 5608-5622.	3.2	17

#	ARTICLE	IF	CITATIONS
55	Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery. <i>European Urology Oncology</i> , 2019, 2, 589-596.	2.6	19
56	High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. <i>Nature Communications</i> , 2019, 10, 4358.	5.8	109
57	Definitive and sustained increase in prostate cancer metastases in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 988-990.	0.8	7
58	Association of Black Race With Prostate Cancer–Specific and Other-Cause Mortality. <i>JAMA Oncology</i> , 2019, 5, 975.	3.4	288
59	Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma. <i>International Journal of Cancer</i> , 2019, 145, 3453-3461.	2.3	18
60	Oligometastatic Prostate Cancer: A Shrinking Subset or an Opportunity for Cure?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 309-320.	1.8	42
61	Prostate cancer in sexual minorities and the influence of HIV status. <i>Nature Reviews Urology</i> , 2019, 16, 404-421.	1.9	17
62	TP53 missense mutation is associated with increased tumor-infiltrating T cells in primary prostate cancer. <i>Human Pathology</i> , 2019, 87, 95-102.	1.1	34
63	SPINK1 expression is enriched in African American prostate cancer but is not associated with altered immune infiltration or oncologic outcomes post-prostatectomy. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 552-559.	2.0	13
64	The Utility of Prostate Specific Antigen Density, Prostate Health Index, and Prostate Health Index Density in Predicting Positive Prostate Biopsy Outcome is Dependent on the Prostate Biopsy Methods. <i>Urology</i> , 2019, 129, 153-159.	0.5	18
65	Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a <i>de novo</i> low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6721-6730.	3.2	74
66	Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications. <i>European Urology Oncology</i> , 2019, 2, 405-412.	2.6	14
67	A comparative effectiveness analysis of the PBCG vs. PCPT risks calculators in a multi-ethnic cohort. <i>BMC Urology</i> , 2019, 19, 121.	0.6	16
68	Biologic Significance of Magnetic Resonance Imaging Invisibility in Localized Prostate Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	1.5	9
69	Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment. <i>World Journal of Urology</i> , 2019, 37, 2623-2629.	1.2	21
70	Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers. <i>Cancer</i> , 2019, 125, 391-397.	2.0	37
71	National practice patterns for lymph node irradiation in 197,000 men receiving external beam radiotherapy for localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 353.e1-353.e8.	0.8	2
72	Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 292-302.	2.0	10

#	ARTICLE	IF	CITATIONS
73	The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. <i>Journal of the National Cancer Institute</i> , 2019, 111, 301-310.	3.0	142
74	Inflammatory Bowel Disease and the Risk of Prostate Cancer. <i>European Urology</i> , 2019, 75, 846-852.	0.9	47
75	African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome. <i>Journal of Urology</i> , 2019, 202, 247-255.	0.2	19
76	A mouse model of prostate cancer bone metastasis in a syngeneic immunocompetent host. <i>Oncotarget</i> , 2019, 10, 6845-6854.	0.8	11
77	Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 479-505.	2.3	943
78	Risk factors for postprostate biopsy infection.. <i>Journal of Clinical Oncology</i> , 2019, 37, 103-103.	0.8	0
79	Percent genome alteration and outcomes after radical prostatectomy in African American men.. <i>Journal of Clinical Oncology</i> , 2019, 37, 24-24.	0.8	0
80	SPINK1 expression and outcomes postprostatectomy in race-specific cohorts.. <i>Journal of Clinical Oncology</i> , 2019, 37, 23-23.	0.8	0
81	Inflammatory bowel disease and risk of prostate cancer: A matched-cohort analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 55-55.	0.8	0
82	Evaluating the clinical, environmental, genetic, and genomic profile of men with early-onset aggressive prostate cancer (PCa).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS333-TPS333.	0.8	0
83	National society-supplied patient materials on prostate cancer screening for the general public: A readability analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, e23188-e23188.	0.8	0
84	Clinical and Genomic Characterization of Low-PSA Prostate-specific Antigen, High-grade Prostate Cancer. <i>European Urology</i> , 2018, 74, 146-154.	0.9	72
85	Gender Representation in Urologic Subspecialties. <i>Urology</i> , 2018, 114, 66-70.	0.5	32
86	Contemporary Incidence and Outcomes of Prostate Cancer Lymph Node Metastases. <i>Journal of Urology</i> , 2018, 199, 1510-1517.	0.2	31
87	Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. <i>European Urology</i> , 2018, 73, 168-175.	0.9	53
88	Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer. <i>European Urology</i> , 2018, 73, 524-532.	0.9	60
89	The effect of socioeconomic status, race, and insurance type on newly diagnosed metastatic prostate cancer in the United States (2004-2013). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 91.e1-91.e6.	0.8	32
90	Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. <i>European Urology</i> , 2018, 74, 107-114.	0.9	54

#	ARTICLE	IF	CITATIONS
91	Prostate Specific Membrane Antigen Targeted ¹⁸ F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. <i>Journal of Urology</i> , 2018, 199, 126-132.	0.2	86
92	Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. <i>JCO Precision Oncology</i> , 2018, 2018, 1-14.	1.5	14
93	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. <i>Journal of Clinical Oncology</i> , 2018, 36, 414-424.	0.8	155
94	The Influence of Decision Aids on Prostate Cancer Screening Preferences: A Randomized Survey Study. <i>Journal of Urology</i> , 2018, 200, 1048-1055.	0.2	2
95	“Real-world” Practice Makes Perfect: Ensuring the Active Component of Active Surveillance for Prostate Cancer. <i>European Urology</i> , 2018, 74, 708-709.	0.9	0
96	Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2018, 24, 3908-3916.	3.2	24
97	Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer. <i>Modern Pathology</i> , 2018, 31, 1539-1552.	2.9	70
98	Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 1376-1383.	1.1	9
99	Transcriptomic Heterogeneity of Favorable-risk Prostate Cancer: Time To Move Past Cancer of the Prostate Risk Assessment (CAPRA) to Clinical-genomic Risk. <i>European Urology</i> , 2018, 74, 453-454.	0.9	1
100	Transcriptomic heterogeneity of androgen receptor activity in primary prostate cancer: Identification and characterization of a low AR-active subclass.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2-2.	0.8	1
101	The influence of decision aids on prostate cancer screening preferences: A randomized survey study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5085-5085.	0.8	0
102	Inflammatory bowel disease and the risk of prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, e17052-e17052.	0.8	0
103	The Role of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Active Surveillance. <i>European Urology</i> , 2017, 71, 174-180.	0.9	75
104	Implementation of a Surgeon-Level Comparative Quality Performance Review to Improve Positive Surgical Margin Rates during Radical Prostatectomy. <i>Journal of Urology</i> , 2017, 197, 1245-1250.	0.2	16
105	Transcriptome evaluation of the relation between body mass index and prostate cancer outcomes. <i>Cancer</i> , 2017, 123, 2240-2247.	2.0	2
106	The evolving genomic landscape of urothelial carcinoma. <i>Nature Reviews Urology</i> , 2017, 14, 215-229.	1.9	89
107	Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. <i>JAMA Oncology</i> , 2017, 3, 1663.	3.4	219
108	TWIST1-WDR5- <i>Hottip</i> Regulates <i>Hoxa9</i> Chromatin to Facilitate Prostate Cancer Metastasis. <i>Cancer Research</i> , 2017, 77, 3181-3193.	0.4	102

#	ARTICLE	IF	CITATIONS
109	Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of <i>TP53</i> Missense Mutation in Prostate Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4693-4703.	3.2	62
110	Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. <i>Cell Reports</i> , 2017, 19, 2045-2059.	2.9	99
111	Dipstick Urinalysis as a Test for Microhematuria and Occult Bladder Cancer. <i>Bladder Cancer</i> , 2017, 3, 45-49.	0.2	17
112	Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 475-484.	1.2	16
113	TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. <i>Clinical Cancer Research</i> , 2017, 23, 7072-7083.	3.2	87
114	Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy. <i>European Urology</i> , 2017, 71, 697-700.	0.9	65
115	Complications After Systematic, Random, and Image-guided Prostate Biopsy. <i>European Urology</i> , 2017, 71, 353-365.	0.9	353
116	Molecular Analysis of Low Grade Prostate Cancer Using a Genomic Classifier of Metastatic Potential. <i>Journal of Urology</i> , 2017, 197, 122-128.	0.2	33
117	Risk of Pathological Upgrading and Up Staging among Men with Low Risk Prostate Cancer Varies by Race: Results from the National Cancer Database. <i>Journal of Urology</i> , 2017, 197, 627-631.	0.2	35
118	Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. <i>Nature Reviews Urology</i> , 2017, 14, 15-25.	1.9	210
119	Progress in Prognosis and Prediction for Men with Prostate Cancer. <i>European Urology</i> , 2017, 72, 32-33.	0.9	1
120	Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy. <i>Oncotarget</i> , 2017, 8, 104182-104192.	0.8	20
121	Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients. <i>Oncotarget</i> , 2017, 8, 50804-50813.	0.8	29
122	Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model. <i>Journal of Clinical Oncology</i> , 2017, 35, 1982-1990.	0.8	76
123	Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. <i>Journal of Clinical Oncology</i> , 2017, 35, 1991-1998.	0.8	176
124	Development and validation of a novel clinical-genomic risk group classification for prostate cancer incorporating genomic and clinicopathologic risk.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5000-5000.	0.8	4
125	Stereotactic ablative radiation therapy for the treatment of oligometastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5020-5020.	0.8	2
126	Neoadjuvant randomized trial of degarelix (Deg) ± cyclophosphamide/GVAX (Cy/GVAX) in men with high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5077-5077.	0.8	12

#	ARTICLE	IF	CITATIONS
127	Race, demographics, and socioeconomics as they relate to newly diagnosed metastatic prostate cancer in the United States.. Journal of Clinical Oncology, 2017, 35, 195-195.	0.8	1
128	Luminal and basal subtyping of prostate cancer.. Journal of Clinical Oncology, 2017, 35, 3-3.	0.8	2
129	Relationships between an androgen receptor output signature (ARoS), AR expression, and poor prostate cancer prognosis in RP tissues.. Journal of Clinical Oncology, 2017, 35, 38-38.	0.8	2
130	The impact of race on perceptions of anxiety after radical prostatectomy.. Journal of Clinical Oncology, 2017, 35, e538-e538.	0.8	0
131	Individual patient level meta-analysis of the performance of the Decipher genomic classifier in high-risk men post-prostatectomy to predict development of metastatic disease.. Journal of Clinical Oncology, 2017, 35, 133-133.	0.8	1
132	Genomic classifier to augment the role of pathological features in identifying optimal candidates for adjuvant radiation therapy in patients with prostate cancer: Development and internal validation of a multivariable prognostic model.. Journal of Clinical Oncology, 2017, 35, 142-142.	0.8	0
133	Luminal and basal subtyping of prostate cancer.. Journal of Clinical Oncology, 2017, 2017, 3-3.	0.8	0
134	Temporal trends and factors associated with overuse of neoadjuvant androgen deprivation therapy in low and very low risk prostate cancer.. Journal of Clinical Oncology, 2017, 35, 28-28.	0.8	0
135	Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e235-e245.	1.8	26
136	Prostate Cancer, Version 1.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 19-30.	2.3	544
137	SPINK1 Defines a Molecular Subtype of Prostate Cancer in Men with More Rapid Progression in an at Risk, Natural History Radical Prostatectomy Cohort. Journal of Urology, 2016, 196, 1436-1444.	0.2	38
138	A Novel Approach for Performing Bone Marrow Aspiration at the Time of Radical Prostatectomy. Urology Case Reports, 2016, 6, 45-46.	0.1	0
139	The History of Prostate Cancer From Antiquity: Review of Paleopathological Studies. Urology, 2016, 97, 8-12.	0.5	15
140	Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report. Urology Case Reports, 2016, 9, 51-54.	0.1	0
141	Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. Lancet Oncology, The, 2016, 17, 1612-1620.	5.1	182
142	Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome. Cancer Research, 2016, 76, 4948-4958.	0.4	147
143	Elevated Prostate Health Index (phi) and Biopsy Reclassification During Active Surveillance of Prostate Cancer. Urology Case Reports, 2016, 7, 64-66.	0.1	2
144	Prostate Health Index (PHI) Predicts High-stage Pathology in African American Men. Urology, 2016, 90, 136-140.	0.5	18

#	ARTICLE	IF	CITATIONS
145	Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor Location. <i>European Urology</i> , 2016, 70, 14-17.	0.9	79
146	The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1777-1786.	3.2	42
147	Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men. <i>European Urology</i> , 2016, 69, 496-504.	0.9	23
148	Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery. <i>European Urology</i> , 2016, 69, 576-581.	0.9	42
149	Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. <i>European Urology</i> , 2016, 69, 157-165.	0.9	206
150	Development and validation of genomic signature to predict ADT treatment failure.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5018-5018.	0.8	1
151	Deciphering the genomic fingerprint of small cell prostate cancer with potential clinical utility.. <i>Journal of Clinical Oncology</i> , 2016, 34, 303-303.	0.8	2
152	Clinical Validation of the 2005 ISUP Gleason Grading System in a Cohort of Intermediate and High Risk Men Undergoing Radical Prostatectomy. <i>PLoS ONE</i> , 2016, 11, e0146189.	1.1	13
153	Development and validation of an ADT resistance signature to predict adjuvant hormone treatment failure.. <i>Journal of Clinical Oncology</i> , 2016, 34, 106-106.	0.8	0
154	Efficacy of early and delayed radiation in a prostatectomy cohort adjusted for genomic and clinical risk.. <i>Journal of Clinical Oncology</i> , 2016, 34, 12-12.	0.8	0
155	Effect of local therapy on the systemic anti-tumor response in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 243-243.	0.8	0
156	Study of PSMA-targeted 18F-DCFPyL PET/CT in the evaluation of men with an elevated PSA following radical prostatectomy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 299-299.	0.8	0
157	Contemporary treatment patterns and short-term outcomes in men with very high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 103-103.	0.8	0
158	The relationship of B7H3 expression to androgen and prostate cancer outcomes in a large natural history cohort of men undergoing prostatectomy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 256-256.	0.8	1
159	Deciphering the genomic fingerprint of small cell prostate cancer with potential clinical utility in radical prostatectomy tissues.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5055-5055.	0.8	0
160	Validation of a genomic risk classifier to predict prostate cancer-specific mortality (PCSM) in high-risk patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5056-5056.	0.8	0
161	Bacterial Prostatitis Enhances 2-Amino-1-Methyl-6-Phenylimidazo[4,5- <i>b</i>]pyridine (PhIP)â€“Induced Cancer at Multiple Sites. <i>Cancer Prevention Research</i> , 2015, 8, 683-692.	0.7	17
162	Instrument Life for Robot-assisted Laparoscopic Radical Prostatectomy and Partial Nephrectomy: Are Ten Lives for Most Instruments Justified?. <i>Urology</i> , 2015, 86, 942-946.	0.5	10

#	ARTICLE	IF	CITATIONS
163	Fluoroquinolone Resistance in the Rectal Carriage of Men in an Active Surveillance Cohort: Longitudinal Analysis. <i>Journal of Urology</i> , 2015, 193, 552-556.	0.2	29
164	Iatrogenic Extraprostatic Extension of Prostate Cancer From a Needle Biopsy. <i>Urology Case Reports</i> , 2015, 3, 56-58.	0.1	1
165	Characterization of 1577 Primary Prostate Cancers Reveals Novel Biological and Clinicopathologic Insights into Molecular Subtypes. <i>European Urology</i> , 2015, 68, 555-567.	0.9	125
166	Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2789-2796.	0.8	127
167	Re: Steven Joniau, Alberto Briganti, Paolo Gontero, et al. Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study. <i>Eur Urol</i> 2015;67:157-64. <i>European Urology</i> , 2015, 68, e11-e12.	0.9	1
168	HES6 promotes prostate cancer aggressiveness independently of Notch signalling. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 1624-1636.	1.6	18
169	Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas. <i>Clinical Cancer Research</i> , 2015, 21, 5619-5629.	3.2	56
170	Reclassification Rates Are Higher Among African American Men Than Caucasians on Active Surveillance. <i>Urology</i> , 2015, 85, 155-160.	0.5	64
171	Magnetic Resonance "invisible Versus Magnetic Resonance "visible Prostate Cancer in Active Surveillance: A Preliminary Report on Disease Outcomes. <i>Urology</i> , 2015, 85, 147-154.	0.5	50
172	Tissue-based genomics to augment post-prostatectomy risk stratification in a natural history cohort.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5059-5059.	0.8	2
173	Recalibration of genomic risk prediction models in prostate cancer to improve individual-level... <i>Journal of Clinical Oncology</i> , 2015, 33, e16122-e16122.	0.8	1
174	Racial Disparities in Oncologic Outcomes After Radical Prostatectomy: Long-term Follow-up. <i>Urology</i> , 2014, 84, 1434-1441.	0.5	56
175	Editorial Comment. <i>Urology</i> , 2014, 84, 1261-1262.	0.5	0
176	Pathological Examination of Radical Prostatectomy Specimens in Men with Very Low Risk Disease at Biopsy Reveals Distinct Zonal Distribution of Cancer in Black American Men. <i>Journal of Urology</i> , 2014, 191, 60-67.	0.2	127
177	Prostate Cancer, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 686-718.	2.3	294
178	Multidisciplinary clinic evaluation changes prostate cancer stage and risk stratification.. <i>Journal of Clinical Oncology</i> , 2014, 32, 91-91.	0.8	0
179	An expression-guided screen for small molecules targeting aggressive prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e16081-e16081.	0.8	0
180	The natural history of progression to PSA recurrence and metastasis among at risk men following radical prostatectomy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5036-5036.	0.8	0

#	ARTICLE	IF	CITATIONS
181	Validation of a genomic classifier that predicts metastatic disease progression in men with biochemical recurrence post radical prostatectomy.. Journal of Clinical Oncology, 2013, 31, 52-52.	0.8	0
182	The role of advanced genetic testing in the management of prostate cancer post radical prostatectomy.. Journal of Clinical Oncology, 2013, 31, 5089-5089.	0.8	0
183	Validation of a genomic classifier that predicts metastatic disease progression in men with biochemical recurrence post radical prostatectomy.. Journal of Clinical Oncology, 2013, 31, 5033-5033.	0.8	1
184	Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomeraseâ€inhibiting therapy. BJU International, 2010, 106, 62-65.	1.3	46
185	Prostate Specific Antigen Testing Among the Elderlyâ€”When To Stop?. Journal of Urology, 2009, 181, 1606-1614.	0.2	63
186	Cystoscopic Management of an Extruded Coil from Arteriovenous Fistula Embolization Using Arthroscopic Instruments. Journal of Endourology, 2008, 22, 1527-1530.	1.1	0
187	Duplex ultrasonography detects clinically significant anomalies of penile arterial vasculature affecting surgical approach to penile straightening. Urology, 2006, 67, 166-169.	0.5	17
188	Prophylactic use of antimicrobials in commonly performed outpatient urologic procedures. Nature Reviews Urology, 2006, 3, 24-31.	1.4	11
189	ADRENAL MYEOLIPOMA. Journal of Urology, 2005, 173, 1760-1760.	0.2	7
190	AMYLOIDOSIS OF THE SEMINAL VESICLE AND HEMATOSPERMIA. Journal of Urology, 2004, 171, 2382-2382.	0.2	8
191	Inguinal bladder hernia. Urology, 2003, 62, 940.	0.5	12